Evotec AG (NASDAQ:EVTCY)

BRIEF

published on 04/23/2024 at 20:43, 6 months 29 days ago

Evotec SE Names Dr. Christian Wojczewski as New CEO

Evotec SE CEO Appointment Corporate Leadership Dr. Christian Wojczewski Medical Industry
BRIEF

published on 04/23/2024 at 20:43, 6 months 29 days ago

Evotec SE nomme le Dr Christian Wojczewski au poste de nouveau PDG

Evotec SE Nomination Du PDG Direction D'entreprise Dr Christian Wojczewski Industrie Médicale
PRESS RELEASE

published on 04/23/2024 at 20:40, 6 months 29 days ago

Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer, effective 01 July 2024, following an extensive selection process. Dr Wojczewski brings over 20 years of management experience in the healthcare industry

Healthcare Industry Evotec SE Chief Executive Officer Dr Christian Wojczewski Management Experience
PRESS RELEASE

published on 04/23/2024 at 20:38, 6 months 29 days ago

EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer. Dr Wojczewski brings over 20 years of management experience, succeeding Dr Mario Polywka

Evotec SE Chief Executive Officer Dr Christian Wojczewski Management Experience Dr Mario Polywka
BRIEF

published on 04/18/2024 at 13:32, 7 months 4 days ago

Evotec and Variant Bio Announce Strategic Partnership to Combat Fibrosis

Strategic Partnership Evotec Variant Bio Fibrosis Treatment Genomic Discovery
BRIEF

published on 04/18/2024 at 13:32, 7 months 4 days ago

Evotec et Variant Bio annoncent un partenariat stratégique pour lutter contre la fibrose

Partenariat Stratégique Evotec Bio De La Variante Traitement De La Fibrose Découverte Génomique
PRESS RELEASE

published on 04/18/2024 at 13:27, 7 months 4 days ago

Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
Evotec SE and Variant Bio partner to discover and develop fibrosis treatments, leveraging cutting-edge genomic discovery platforms. Agreement includes research funding and milestone/royalty payments

Evotec SE Research Funding Variant Bio Genomic Discovery Fibrosis Treatments
BRIEF

published on 04/17/2024 at 15:05, 7 months 5 days ago

Evotec SE Set to Announce 2023 Fiscal Year Results

Financial Results Life Sciences Evotec SE Fiscal Year 2023 Stakeholder Engagement
BRIEF

published on 04/17/2024 at 15:05, 7 months 5 days ago

Evotec SE s'apprête à annoncer ses résultats pour l'exercice 2023

Résultats Financiers Evotec SE Exercice 2023 Sciences De La Vie Engagement Des Parties Prenantes
PRESS RELEASE

published on 04/17/2024 at 15:00, 7 months 5 days ago

Evotec SE to announce results for fiscal year 2023 on 24 April 2024
Evotec SE will announce its financial results for 2023 with a conference call on 24 April 2024. The company focuses on developing therapeutics through a unique business model

Financial Results Conference Call Evotec SE Therapeutics Business Model

Published on 11/22/2024 at 18:45, 3 hours 54 minutes ago

CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/22/2024 at 16:00, 6 hours 39 minutes ago

Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 6 hours 44 minutes ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 7 hours 24 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 7 hours 54 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 4 hours 24 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 4 hours 39 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 4 hours 45 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 5 hours 43 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 6 hours 39 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 4 hours 54 minutes ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 6 hours 24 minutes ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 8 hours 4 minutes ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 8 hours 4 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 15 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News